Inspiratory muscle training protocol for patients with chronic obstructive pulmonary disease (IMTCO study): a multicentre randomised controlled trial

Noppawan Charususin, Rik Gosselink, Marc Decramer, Alison McConnell, Didier Saey, Francois Maltais, Eric Derom, Stefanie Vermeersch, Hanneke van Helvoort, Yvonne Heijdra, Mariska Klaassen, Rainer Glöckl, Klaus Kenn, Daniel Langer, Noppawan Charususin, Rik Gosselink, Marc Decramer, Alison McConnell, Didier Saey, Francois Maltais, Eric Derom, Stefanie Vermeersch, Hanneke van Helvoort, Yvonne Heijdra, Mariska Klaassen, Rainer Glöckl, Klaus Kenn, Daniel Langer

Abstract

Introduction: Inspiratory muscle training (IMT) has been applied during pulmonary rehabilitation in patients with chronic obstructive pulmonary disease (COPD). However, it remains unclear if the addition of IMT to a general exercise training programme leads to additional clinically relevant improvements in patients with COPD. In this study, we will investigate whether the addition of IMT to a general exercise training programme improves 6 min walking distance, health-related quality of life, daily physical activity and inspiratory muscle function in patients with COPD with inspiratory muscle weakness.

Methods and analysis: Patients with COPD (n=170) with inspiratory muscle weakness (Pi,max <60 cm H2O or <50%pred) will be recruited to a multicentre randomised placebo controlled trial of IMT and allocated into one of the two groups. Patients in both groups will follow a 3 month general exercise training programme, in combination with home-based IMT. IMT will be performed with a recently developed device (POWERbreathe KH1). This device applies an inspiratory load that is provided by an electronically controlled valve (variable flow resistive load). The intervention group (n=85) will undertake an IMT programme at a high intensity (≥50% of their Pi,max), whereas the placebo group (n=85) will undertake IMT at a low training intensity (≤10% of Pi,max). Total daily IMT time for both groups will be 21 min (6 cycles of 30 breaths). Improvement in the 6 min walking distance will be the primary outcome. Inspiratory muscle function, health-related quality of life and daily physical activity will be assessed as secondary outcomes.

Ethics and dissemination: Ethics approval has been obtained from relevant centre committees and the study has been registered in a publicly accessible clinical trial database. The results will be easily interpretable and should immediately be communicated to healthcare providers, patients and the general public.

Results: This can be incorporated into evidence-based treatment recommendations for clinical practice.

Clinicaltrialsgov: NCT01397396.

Figures

Figure 1
Figure 1
Comparison between constant threshold (threshold) and variable resistive inspiratory muscle training (POWERbreathe KH1).

References

    1. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765–73
    1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532–55
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011 Global Strategy for the Diagnosis, Management and Prevention of COPD. Type: Internet Communication.
    1. O'Donnell DE, Travers J, Webb KA, et al. Reliability of ventilatory parameters during cycle ergometry in multicentre trials in COPD. Eur Respir J 2009;34:866–74
    1. Hamilton N, Killian KJ, Summers E, et al. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995;152:2021–31
    1. Lacasse Y, Martin S, Lasserson TJ, et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. A Cochrane systematic review. Eura Medicophys 2007;43:475–85.
    1. Decramer M, Demedts M, Rochette F, et al. Maximal transrespiratory pressures in obstructive lung disease. Bull Eur Physiopathol Respir 1980;16:479–90
    1. Polkey MI, Kyroussis D, Hamnegard CH, et al. Diaphragm strength in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;154:1310–17
    1. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med 2003;168:10–48
    1. Begin P, Grassino A. Inspiratory muscle dysfunction and chronic hypercapnia in chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:905–12
    1. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996;153:976–80
    1. Nici L, Donner C, Wouters E, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006;173:1390–413
    1. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007;131:4S–42S
    1. Gosselink R, De VJ, Van den Heuvel SP, et al. Impact of inspiratory muscle training in patients with COPD: what is the evidence? Eur Respir J 2011;37:416–25
    1. Geddes EL, O'Brien K, Reid WD, et al. Inspiratory muscle training in adults with chronic obstructive pulmonary disease: an update of a systematic review. Respir Med 2008;102:1715–29
    1. Ambrosino N. The case for inspiratory muscle training in COPD. Eur Respir J 2011;37:233–5
    1. McConnell AK. CrossTalk opposing view: respiratory muscle training does improve exercise tolerance. J Physiol 2012;590:3397–8
    1. Patel MS, Hart N, Polkey MI. CrossTalk proposal: training the respiratory muscles does not improve exercise tolerance. J Physiol 2012;590:3393–5
    1. Polkey MI, Moxham J, Green M. The case against inspiratory muscle training in COPD. Against Eur Respir J 2011;37:236–7
    1. Decramer M. Response of the respiratory muscles to rehabilitation in COPD. J Appl Physiol 2009;107:971–6
    1. Winkelmann ER, Chiappa GR, Lima CO, et al. Addition of inspiratory muscle training to aerobic training improves cardiorespiratory responses to exercise in patients with heart failure and inspiratory muscle weakness. Am Heart J 2009;158:768–7
    1. Luo YM, Hopkinson NS, Polkey MI. Tough at the top: must end-expiratory lung volume make way for end-inspiratory lung volume? Eur Respir J 2012;40:283–5
    1. Doig GS, Simpson F. Randomization and allocation concealment: a practical guide for researchers. J Crit Care 2005;20:187–91
    1. Troosters T, Gosselink R, Decramer M. Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med 2000;109:207–12
    1. Puhan MA, Chandra D, Mosenifar Z, et al. The minimal important difference of exercise tests in severe COPD. Eur Respir J 2011;37:784–90
    1. Mathiowetz V, Dove M, Kashman N, et al. Grip and pinch strength: normative data for adults. Arch Phys Med Rehabil 1985;66:69–72
    1. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81
    1. Langer D, Jacome C, Hoffman M, et al. Comparison of two high intensity inspiratory muscle training programs in patients with COPD: A randomized controlled trial. Am J Respir Crit Care Med 2013;187:A2566
    1. Black LF, Hyatt RE. Maximal respiratory pressures: normal values and relationship to age and sex. Am Rev Respir Dis 1969;99:696–702
    1. Rochester DF, Arora NS. Respiratory muscle failure. Med Clin North Am 1983;67:573–97
    1. Langer D, Jacome C, Charususin N, et al. Measurement validity of an electronic inspiratory loading device during a loaded breathing task in patients with COPD. Respir Med 2013;107:633–5
    1. Jones NL, Makrides L, Hitchcock C, et al. Normal standards for an incremental progressive cycle ergometer test. Am Rev Respir Dis 1985;131:700–8
    1. Yan S, Kaminski D, Sliwinski P. Reliability of inspiratory capacity for estimating end-expiratory lung volume changes during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;156:55–9
    1. Guyatt GH, Pugsley SO, Sullivan MJ, et al. Effect of encouragement on walking test performance. Thorax 1984;39:818–22
    1. Troosters T, Gosselink R, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999;14:270–4
    1. Langer D, Gosselink R, Sena R, et al. Validation of two activity monitors in patients with COPD. Thorax 2009;64:641–2
    1. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319–38
    1. MacIntyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005;26:720–35
    1. Decramer M, Lacquet LM, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994;150:11-6.
    1. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987;42:773–8
    1. Puhan MA, Behnke M, Frey M, et al. Self-administration and interviewer-administration of the German Chronic Respiratory Questionnaire: instrument development and assessment of validity and reliability in two randomised studies. Health Qual Life Outcomes 2004;2:1.
    1. Bourbeau J, Maltais F, Rouleau M, et al. French-Canadian version of the Chronic Respiratory and St George's Respiratory questionnaires: an assessment of their psychometric properties in patients with chronic obstructive pulmonary disease. Can Respir J 2004;11:480–6
    1. Wijkstra PJ, TenVergert EM, Van AR, et al. Reliability and validity of the chronic respiratory questionnaire (CRQ). Thorax 1994;49:465–7
    1. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70
    1. Vickers AJ, Altman DG. Statistics notes: analysing controlled trials with baseline and follow up measurements. BMJ 2001;323:1123–4

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅